Skip to main content
SpringerLink
Log in

N-nitrosodimethylamine-contaminated valsartan

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pottegard A, et al. Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study. BMJ 2018: k3851, No. 362, 12 Sep 2018. Available from: URL: https://doi.org/10.1136/bmj.k3851.

    Article  Google Scholar 

  2. Banzi R, et al. Regulatory response to contaminated valsartan. BMJ 2018: k3955, No. 362, 12 Sep 2018. Available from: URL: https://doi.org/10.1136/bmj.k3855.

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

N-nitrosodimethylamine-contaminated valsartan. Reactions Weekly 1720, 12 (2018). https://doi.org/10.1007/s40278-018-51806-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-51806-6

Search

Navigation